AL-3789: a novel ophthalmic angiostatic steroid

Bibliography

• MILLER JW, STINSON WG, FOLKMAN J: Regression of ex-perimental iris neovascularization with systemic alpha-interferon. Ophthalmology (1993) 100:9–14.
   PubMed Web of Science ®Google Scholar
• GUYER DR, ADAMIS AP, YANNUZZI LA et al.: Interferonalpha-2a is ineffective for patients with choroidal neo-vascularization secondary to age-related macular de-generation. Arch. Ophthalmot (1997) 115:865–872.
   PubMedGoogle Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Tha-lidomide is an inhibitor of angiogenesis. Proc. Natt Acad. Sci. USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• AIELLO LP: Vascular endothelial growth factor and theeye. Arch. Ophthalmot (1996) 114(10):1252–1254.
   PubMed Web of Science ®Google Scholar
• ADAMIS AP, SHIMA DT, TOLENTINO MJ et al Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in nonhu-man primate. Arch. Ophthalmot (1996) 114 66–71
   PubMed Web of Science ®Google Scholar
• AIELLO LP, PIERCE EA, FOLEY ED et al.: Suppression ofretinal neovascularization in vivo by inhibition of vas-cular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci, USA (1995) 92(23):10457–10461.
   PubMed Web of Science ®Google Scholar
• ROBINSON GS, PIERCE EA, ROOK SL et al.: Oligodeoxynu-cleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci, USA (1996) 93:4851–4856.
   PubMed Web of Science ®Google Scholar
• SMITH LEH, KOPCHICK JJ, CHEN W et al.: Essential role ofgrowth hormone in ischemia-induced retinal neovas-cularization. Science (1997) 276:1706–1709.
   PubMed Web of Science ®Google Scholar
• DANIS RP, BINGAMAN DP, YANG Y, JIROUSEK M: Inhibi-tion of ocular neovascularization due to experimental branch retinal vein occlusion by a specific protein kinase-C13 inhibitor, LY333531. Invest. Ophthalmol, Vis, Sci, (1997) 38(4):S964.
   Google Scholar
• FRIEDLANDER M, BROOKS PC, SHAFFER RW et at: Defini-tion of two angiogenic pathways by distinct alpha v in-tegrins. Science (1995) 270:1500–1502.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER M, THEESFELD CL, SUGITA Metal. Involve-ment of integrins oc,133 and oc,135 in ocular neovascular diseases. Proc. Natl. Acad. Sci, USA (1996) 93:9764–9769.
   Google Scholar
• GOOD DJ, POLVERINI PJ, RASTINEJAD F et al.: A tumour suppressor-dependent inhibitor of angiogenesis is im-munologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci, USA (1990) 87:6624–6628.
   PubMed Web of Science ®Google Scholar
• KUSAKA M, SUDO K, FUJITA T et al.: Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem, Biophys, Res. Comm. (1991) 174:1070–1076.
   PubMed Web of Science ®Google Scholar
• AVERY RL, CONNOR TB, FARAZDAGHI M: Systemic ami-loride inhibits experimentally induced neovasculariza-tion. Arch. Ophthalmot (1990) 108:1474–1476.
   PubMed Web of Science ®Google Scholar
• CRUM R, SZABO S, FOLKMAN J: A new class of steroids in-hibits angiogenesis in the presence of heparin or a heparin fragment. Science (1985) 230:1375–1378.
   PubMed Web of Science ®Google Scholar
• LI WW, CASEY R, GONZALEZ EM, FOLKMAN J: Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest. Ophthalmol, Vis, Sci, (1991) 32:2898–2905.
   PubMed Web of Science ®Google Scholar
• PROIA AD, HIRAKATA A, MCINNES JS, SCROGGS MW, PARIKH I: The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovasculari-zation in the rat. Exp. Eye Res. (1993) 57:693–698.
   PubMed Web of Science ®Google Scholar
• MCNATT L, LANE D, CLARK AF: Cortisol metabolism in the chicken embryo chorioallantoic membrane (CAM). J. Steroid Biochem, Mot Biol. (1992) 42 (7):687–693.
   PubMed Web of Science ®Google Scholar
• BENEZRA D, GRIFFIN B, MAFTZIR G et al.: Inhibition of rabbit corneal noevascularization by AL-3789 topical ophthalmic formulations. Invest. Ophthalmol, Vis, Sci, (1997) 38:1954–1962.
   PubMed Web of Science ®Google Scholar
• TOLMAN BL, COLLIER RJ, CLARK AF, PENN JS: Effects of an angiostatic steroid on neovascularization in the rat model of ROP. Invest. Ophthalmol, Vis, Sci, (1995) 36(4)454.
   Google Scholar
• FOLKMAN J: Clinical applications of research in angio-genesis. New Engl. J. Med. (1995) 333:1757–1763.
   PubMed Web of Science ®Google Scholar
• MA D, CLARK AF, ALIZADEH H, MELLON J, NIEDERKORN JY: Inhibition of intraocular tumour growth by topical application of the angiostatic agent AL-3789. Invest. Ophthalmol, Vis, Sci, (1995) 36(4):2265.
   Google Scholar
• SHIMA DT, ADAMIS AP, FERRARA N et al.: Hypoxic induc-tion of endothelial growth factors in retinal cells: iden-tification of and characterisation of vascular endothelial growth factor (VEGF) as the mitogen. MoL Med. (1995) 1(2):182–193.
   PubMed Web of Science ®Google Scholar
• ASHINO-FUSE H, TAKANO Y, SHIMAMURA M, IWAGUCHI T: Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen acti-vator in bovine endothelial cells. Int. J. Cancer (1989) 44:859–864.
   PubMed Web of Science ®Google Scholar
• BLEI F, WILSON EL, MIGNATTI P, RIFKIN DB: Mechanism of action of angiostatic steroids: suppression of plasmi-nogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J. Cell. PhysioL (1993) 155:568–578.
   PubMed Web of Science ®Google Scholar
• CLARK AF: Glucocorticoids, ocular hypertension and glaucoma. J. Glaucoma (1995) 4:354–369.
   PubMedGoogle Scholar
• CLARK AF, MCNATT L, KNEPPER PA: Angiostatic steroids as a new class of IOP lowering agents. Invest. OphthalmoL Vis, Sci, (1994) 35(4):2734.
   PubMedGoogle Scholar